485 results on '"Neben, Kai"'
Search Results
2. Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma—Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries
3. Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma
4. Data from Targeting the BRAF V600E Mutation in Multiple Myeloma
5. Supplementary Table 1 from Targeting the BRAF V600E Mutation in Multiple Myeloma
6. Supplementary Data File 1 from Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical Routine
7. Supplementary Table 1 from Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical Routine
8. Supplementary Methods, Legends, Table 2-3, Figures 1-4 from Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical Routine
9. Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
10. Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study
11. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease
12. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6
13. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)
14. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial
15. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial
16. Poor Mobilization of Hematopoietic Stem Cells—Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation
17. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma
18. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
19. Changes in severity of influenza A(H1N1)pdm09 infection from pandemic to first postpandemic season, Germany
20. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma
21. Meeting report of the third Heidelberg myeloma workshop: current status and developments in diagnosis and therapy of multiple myeloma
22. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
23. Diagnostik und Therapie des CUP-Syndroms: Neue Chancen durch „targeted therapies“?
24. Current status and developments in diagnosis and therapy of multiple myeloma
25. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial
26. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone
27. Diagnostik des multiplen Myeloms
28. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype
29. Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide
30. Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes
31. Autologous retransplantation for patients with recurrent multiple myeloma: A single-center experience with 200 patients
32. Hepatitis B virus infection is associated with deletion of chromosome 8p in multiple myeloma
33. Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study
34. Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology
35. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone
36. Clinical outcome of patients with follicular lymphoma and bulky disease after Rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy
37. Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up
38. Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials
39. High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia
40. Expression of centrosome-associated gene products is linked to tetraploidization in mantle cell lymphoma
41. Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma
42. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
43. Leitlinie - ICD-10: C80.- : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
44. A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials
45. Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal
46. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
47. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
48. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
49. Where is the primary tumour?
50. AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.